SynAgile Corporation Announces Positive Phase 2 Top Line Results for DopaFuse® Levodopa-Carbidopa Delivery System SAN JOSE, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- SynAgile Corporation (www.SynAgile.com) today announced positive results from its Phase 2 clinical trial of continuous levodopa-carbidopa (LD-CD)...

SynAgile Completes Enrollment of its Phase 2 Clinical Trial of its DopaFuse Delivery System SAN JOSE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SynAgile Corporation (www.SynAgile.com) is pleased to announce it has completed enrollment of its clinical trial evaluating the DopaFuse Delivery...

First Patient Treated with the DopaFuse® Delivery System WILSON, Wyo., Oct. 27, 2021 (GLOBE NEWSWIRE) -- SynAgile is pleased to announce treatment of the first patient with the DopaFuse Delivery System in the SCOL (Study of Continuous Oral Levodopa)...

SynAgile Corporation Announces Closing of Financing, Appointment of Mr. Michael McNamara to the Board of Directors, and Appointment of Dr. C. Warren Olanow as Chief Medical Officer WILSON, Wyoming, Sept. 22, 2021 (GLOBE NEWSWIRE) -- SynAgile Corporation (www.SynAgile.com), a privately held pharmaceutical company that develops and commercializes drug delivery systems using its...